LRRC15 Protein, Cynomolgus/Rhesus macaque (HEK293, His)

LRRC15 is a cell membrane-expressed protein belonging to the LRR superfamily. Involved in cell-cell and cell-ECM interactions. The LRRC15 protein regulates the infectivity of SARS-CoV-2 by interacting with its spike protein. LRRC15 activates the β1-integrin /FAK signaling pathway to promote ovarian cancer metastasis. LRRC15 Protein, Cynomolgus/Rhesus macaque (HEK293, His) is the recombinant cynomolgus-derived LRRC15 protein, expressed by HEK293 , with C-His labeled tag.

LRRC15 is a cell membrane-expressed protein belonging to the LRR superfamily. Involved in cell-cell and cell-ECM interactions. The LRRC15 protein regulates the infectivity of SARS-CoV-2 by interacting with its spike protein. It does not act as an entry receptor for SARS-CoV-2, but when it is expressed on nearby cells, it isolates virions and trans inhibits SARS-CoV-2 infection of ACE2 (+) cells. In addition, the LRRC15 protein directly interacts with the RBD domain of the human coronavirus SARS-CoV-2 spike protein, resulting in the isolation of virions on the cell surface. LRRC15 activates the β1-integrin /FAK signaling pathway to promote ovarian cancer metastasis, and the LRRC15-targeted antiboy-drug conjugate ABBV-085 was found to inhibit ovarian cancer metastasis in preclinical models^[1][2][3].

Rhesus Macaque; Cynomolgus

HEK293

C-8*His

G7NYR2/F7FSB9 (Y22-G538)

102144360  [NCBI]/707574

Extracellular Domain

YYGCPSECTCSRASQVECTGARIVAVPTPLPWNAMSLQILNTHITELSESPFLNISALIALRIEKNELSHIMPGAFRNLGSLRYLSLANNKLQVLPIGLFQGLDSLESLLLSSNQLVQIQPAHFSQCSNLKELQLHGNHLEYIPDGAFDHLVGLTKLNLGKNSLTHISPRVFQHLGNLQVLRLYENRLTDIPMGTFDGLVNLQELALQQNQIGLLSPGLFHNNHNLQRLYLSNNHISQLPPSIFMQLPQLNRLTLFGNSLKELSPGIFGPMPNLRELWLYDNHITSLPDNVFSNLRQLQVLILSRNQISFISPGAFNGLTELRELSLHTNALQDLDGNVFRMLANLQNISLQNNRLRQLPGNIFANVNGLMTIQLQNNQLENLPLGIFDHLGKLCELRLYDNPWRCDSDILPLRNWLLLNQPRLGTDTVPVCFSPANVRGQSLIIINVNVAVPSVHVPEVPSYPETSWYPDTSSYPDTTSISSTTELTSPVEDYTDLTTIQVTDDRSVWGMTQAQSG

Approximately 70-90 kDa, based on SDS-PAGE under reducing conditions, due to the glycosylation.

≥ 95%, as determined by reducing SDS-PAGE.

<1 EU/μg, determined by LAL method.

• [1]. Ray U, et al. Exploiting LRRC15 as a Novel Therapeutic Target in Cancer. Cancer Res. 2022 May 3;82(9):1675-1681.  [Content Brief]

  [2]. Berkowitz RL, et al. The Elusive Coreceptors for the SARS-CoV-2 Spike Protein. Viruses. 2022 Dec 25;15(1):67.  [Content Brief]

  [3]. Ray U, et al. Targeting LRRC15 Inhibits Metastatic Dissemination of Ovarian Cancer. Cancer Res. 2022 Mar 15;82(6):1038-1054.  [Content Brief]